|
|
Article: Point Therapeutics Down 68% On Talabostat Clinical Hold.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
Shares of Point Therapeutics Inc. fell 68 percent to a 52-week low of 14 cents on Monday after the FDA placed a hold on the company's talabostat clinical program.
The hold followed an Independent Data Monitoring Committee's recommendation to halt two Phase III trials of talabostat in non-small cell lung cancer (NSCLC) after an interim analysis determined that neither trial was likely to meet its primary endpoint of median progression-free survival (PFS) or its secondary endpoint of overall survival.
In fact, in a trial evaluating talabostat plus Taxotere (docetaxel, Sanofi-Aventis Group) versus Taxotere plus placebo, the talabostat ...